Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xingya Li

Showing results (111-120 of 146) with videos related to

Pageof 15
Sort By:
Cancer Communications (London, England)|October 2, 2025
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trialsJian Li, Ting Deng, Yanhong Gu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2021
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 TrialShengxiang Ren, Jianhua Chen, Xingxiang Xu, et al.
Cancer Communications (London, England)|May 29, 2025
First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trialYing Cheng, Shuang Zhang, Liang Han, et al.
Cancer Cell|June 18, 2026
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancerJun Liao, Wenxiu Yao, Yan Yu, et al.
Eclinicalmedicine|April 25, 2023
Gumarontinib in patients with non-small-cell lung cancer harbouring <i>MET</i> exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trialYongfeng Yu, Jianya Zhou, Xingya Li, et al.
Nature Cancer|June 15, 2023
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Ziping Wang, Meili Sun, et al.
The New England Journal of Medicine|October 22, 2025
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, <i>EGFR</i>-Mutated Advanced NSCLCWenfeng Fang, Lin Wu, Xiangjiao Meng, et al.
Molecular Cancer|January 4, 2022
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trialTao Jiang, Jianhua Chen, Xingxiang Xu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 29, 2021
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 StudyXinghao Ai, Yueyin Pan, Jianhua Shi, et al.
Lancet (London, England)|May 29, 2026
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trialAnwen Xiong, Wenxiu Yao, Wei Zheng, et al.
Pageof 15

Showing results (111-120 of 146) with videos related to

Sort By:
Pageof 15
Cancer Communications (London, England)|October 2, 2025
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trialsJian Li, Ting Deng, Yanhong Gu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2021
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 TrialShengxiang Ren, Jianhua Chen, Xingxiang Xu, et al.
Cancer Communications (London, England)|May 29, 2025
First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trialYing Cheng, Shuang Zhang, Liang Han, et al.
Cancer Cell|June 18, 2026
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancerJun Liao, Wenxiu Yao, Yan Yu, et al.
Eclinicalmedicine|April 25, 2023
Gumarontinib in patients with non-small-cell lung cancer harbouring <i>MET</i> exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trialYongfeng Yu, Jianya Zhou, Xingya Li, et al.
Nature Cancer|June 15, 2023
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Ziping Wang, Meili Sun, et al.
The New England Journal of Medicine|October 22, 2025
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, <i>EGFR</i>-Mutated Advanced NSCLCWenfeng Fang, Lin Wu, Xiangjiao Meng, et al.
Molecular Cancer|January 4, 2022
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trialTao Jiang, Jianhua Chen, Xingxiang Xu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 29, 2021
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 StudyXinghao Ai, Yueyin Pan, Jianhua Shi, et al.
Lancet (London, England)|May 29, 2026
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trialAnwen Xiong, Wenxiu Yao, Wei Zheng, et al.
Pageof 15